Literature DB >> 20942842

Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism.

Henrik Gregersen1, Mette Nørgaard, Marianne T Severinsen, Malene C Engebjerg, Paw Jensen, Henrik T Sørensen.   

Abstract

BACKGROUND: Patients with multiple myeloma are at increased risk of venous thromboembolism (VTE), but little information is available on VTE risk in patients with the precursor condition monoclonal gammopathy of undetermined significance (MGUS).
OBJECTIVE: To evaluate the risk of VTE and its impact on mortality in patients with MGUS. PATIENTS AND METHODS: We identified 1610 patients with MGUS and no prior diagnosis of VTE during the 1978-2005 period in North Jutland County, Denmark. We used the Danish Central Population Registry to select 16,100 general population comparison cohort members with no prior VTE diagnosis, matched with the MGUS patients by age, sex, and comorbidity. Follow-up data on VTE incidence in the two groups were obtained from the Danish National Patient Registry covering all Danish hospitals. Time-varying Cox regression analysis was used to compute the incidence rate ratio (IRR) of VTE and the mortality rate ratio (MRR) for MGUS patients who developed VTE compared to MGUS patients without VTE.
RESULTS: In the MGUS cohort, 50 VTE events were identified during 12,594 person-years (PY) of follow-up, corresponding to an incidence rate of 4.0 VTEs/1000 PY. The IRR for VTE among MGUS patients compared to the comparison cohort was 1.37 (95% confidence interval (CI): 1.00-1.88). Of the 50 MGUS patients with VTE, one was later diagnosed with malignant transformation. The adjusted MRR for MGUS patients with VTE compared to MGUS patients without VTE was 1.94 (95% CI: 1.36-2.77).
CONCLUSIONS: MGUS is a risk factor for VTE, and VTE is a marker for increased mortality among MGUS patients.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20942842     DOI: 10.1111/j.1600-0609.2010.01539.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  11 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 2.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

3.  Venous thromboembolism and cancer risk among elderly adults in the United States.

Authors:  Morgan A Marks; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-08       Impact factor: 4.254

4.  Monoclonal gammopathy of undetermined significance associated with blue finger syndrome.

Authors:  Alaa M Ali; Aibek E Mirrakhimov
Journal:  BMJ Case Rep       Date:  2013-01-03

5.  Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Maeve P Crowley; Maeve P Crowely; Shane Quinn; Eoin Coleman; Joseph A Eustace; Oonagh M Gilligan; Susan I O'Shea; Susan I O Shea
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

6.  Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.

Authors:  Teresa E Goebel; Nicholas K Schiltz; Kenneth J Woodside; Aiswarya Chandran Pillai; Paolo F Caimi; Hillard M Lazarus; Siran M Koroukian; Erica L Campagnaro
Journal:  Clin Transplant       Date:  2015-08-20       Impact factor: 2.863

7.  Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry.

Authors:  Henrik Gregersen; Caroline Brenner Larsen; Anne Haglund; Rikke Mortensen; Niels Frost Andersen; Mette Nørgaard
Journal:  Clin Epidemiol       Date:  2013-08-27       Impact factor: 4.790

8.  A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK.

Authors:  Indra Ramasamy
Journal:  J Blood Med       Date:  2020-06-11

9.  A case of monoclonal gammopathy of undetermined significance and minimal change disease complicated by bilateral pulmonary emboli.

Authors:  Thanuja Neerukonda; Alexandra Witt; Arsen Tan; Bilal Farooqi; Yasna Chaudhary; Christina Kovacs; Luis Silva
Journal:  SAGE Open Med Case Rep       Date:  2022-08-12

Review 10.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.